more_reports

Interim Data From TID Trial Are Positive

  ()
Sernova Biotherapeutics Inc.'s (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) regenerative treatment delivered via its Cell Pouch Bio-hybrid Organ is proving to result in insulin independence, among other outcomes. Read what one analyst says are the implications of this clear medical benefit.
Tags: Regenerative MedicineMedical Devices

Biotech Firm Unlocks Alzheimer's Market with U.S. Clinic Launch

  ()
Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGW0:XFRA) has acquired NoBrainer Imaging, unlocking Alzheimer's PET scan clinics in Florida, Los Angeles, five select U.S. cities, and Canada. Read more to explore the growth potential.
Tags: Biotechnology / Pharmaceuticals

Biopharma Receives PDUFA Date for Lead Program

Research Report
  ()
This is a critical milestone for the company and significant for the space given the lack of approved therapies, noted a D. Boral Capital report.
Tags: Biotechnology / Pharmaceuticals

New Cell Treatment for Bladder Cancer Shows Promise

Research Report
  ()
This investigative therapy is "uniquely positioned to occupy a distinct segment" within the evolving and crowded space, noted an H.C. Wainwright & Co. report.
Tags: Biotechnology / Pharmaceuticals

Biopharma Shares Efficacy Data at AUA Meeting

Research Report
  ()
These results and input from key opinion leaders boost "our enthusiasm for this candidate's prospects as a treatment for non-muscle, invasive bladder cancer, noted an Oppenheimer report.
Tags: Biotechnology / Pharmaceuticals

Biotech Co. Achieves Remarkable Cancer Treatment Results in Trial

  ()
Clinical-stage biopharmaceutical company Protara Therapeutics Inc. (TARA:NASDAQ) announces updated results from its trials of a drug for high-risk non-muscle invasive bladder cancer (NMIBC). Read why analysts are recommending this biopharmaceutical stock.
Tags: Biotechnology / Pharmaceuticals

Biotech Firm Uncovers Long-Term Cancer Breakthrough in Nevada

  ()
UroGen Pharma Ltd. (URGN:NASDAQ) unveiled nearly four years of durable response for JELMYTO in Nevada, offering a breakthrough for low-grade upper tract cancer patients. See how UroGen Pharmas breakthrough data could reshape non-surgical cancer treatments and drive future growth in the oncology sector.
Tags: Biotechnology / Pharmaceuticals

One Co. With Cell Holding Device Stands Out in T1D Space

Research Report
  ()
Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) alone has shown favorable outcomes in a trial when patients with this disease were treated with an implanted device containing donor islets, noted an H.C. Wainwright & Co. report.
Tags: Medical DevicesRegenerative Medicine

Biotech Company Reports Promising Neurological Treatment in Clinical Study

  ()
Clinical-stage biotechnology company Coya Therapeutics Inc. (COYA:NASDAQ) announces positive interim results of a study for the treatment of patients with frontotemporal dementia (FTD). Read to see what catalysts one analyst said the stock can look forward to this year.
Tags: Biotechnology / Pharmaceuticals

Biopharma Company Leverages AI-Powered Platform for Cancer Breakthroughs

  ()
Rakovina Therapeutics Inc. (RKV:TSX.V) announced its scientific advisor and collaborator Dr. Artem Cherkasov was recently recognized as a leader in AI-driven drug development. Find out which analysts recently initiated coverage on the company.
Tags: Biotechnology / PharmaceuticalsLife Sciences Tools & Diagnostics

Biotech Discovers Revolutionary Immunotherapy in Houston

Research Report
  ()
Coya Therapeutics Inc. (COYA:NASDAQ) recently reported a statistically significant Treg improvement in FTD patients with its dual-action immunotherapy, showing promising neuroprotection, according to a D. Boral research note.
Tags: Biotechnology / Pharmaceuticals

Analyst Reveals Undervalued Pharmaceutical Gem in Canada

Research Report
  ()
In a recent research note from Leede Financial Inc. analyst Dr. Douglas Loe said Theratechnologies Inc. (TH:TSX; THTX:NASDAQ) has long term potential.
Tags: Biotechnology / Pharmaceuticals

Four-Year Data on New Drug for Early AD Positive

Research Report
  ()
Long-term treatment with this small molecule seems feasible given its safety and tolerability profile, noted an H.C. Wainwright & Co. report.
Tags: Biotechnology / Pharmaceuticals

Rest of 2025 Rich With Catalysts for Immunotherapy Co.

Research Report
  ()
These anticipated events will advance the oncology firm's lead candidate, for lung-only metastatic osteosarcoma, toward commercialization, noted a D. Boral Capital report.
Tags: Biotechnology / Pharmaceuticals

New Drug for Early AD Shown to be Efficacious, Safe

Research Report
  ()
Trial participants exhibited improvements in cognitive function and activities of daily living, noted a D. Boral Capital report.
Tags: Biotechnology / Pharmaceuticals

Biotech Firm Uncovers Gene Therapy Breakthrough in Portugal

  ()
Beam Therapeutics Inc. (BEAM:NASDAQ) shows strong momentum with positive analyst ratings and new data from its BEAM-302 trial in AATD. Find out why experts see major upside potential.
Tags: Biotechnology / Pharmaceuticals

Expert Investing Ideas

Streetwise Reader Icon Streetwise Key Charts
Pharma Biotech & Life Sci

Get Our Streetwise Reports' Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

New Therapy for AATD Could be Best in Class

Research Report
  ()
Updated trial data show it to be safe and efficacious and have a dual mechanism of action, noted an H.C. Wainwright & Co. report.
Tags: Biotechnology / Pharmaceuticals

Share Price Appreciation of Biotech Due Over Next Six Months

Research Report
  ()
Given its robust pipeline, numerous milestones for this Outperform-rated company are slated to occur in the near-term, noted a Wedbush report.
Tags: Biotechnology / Pharmaceuticals

Biotech Company Finds High-Impact Alzheimer's Therapy in Europe

  ()
Anavex Life Sciences Corp. (AVXL:NASDAQ) earned positive analyst coverage following new long-term data for blarcamesine in early Alzheimer's disease. Experts pointed to safety, durability, and potential approval pathways. Read more about what they said.
Tags: Biotechnology / Pharmaceuticals

Immunotherapy Company Finds Rare Cancer Breakthrough in U.S.

  ()
OS Therapies Inc. (OSTX:NYSEAMERICAN) announced that its lead drug OST-HER2 was granted Orphan Drug Designation by the FDA for osteosarcoma. Read how the designation could accelerate development and create new investor interest.
Tags: Biotechnology / Pharmaceuticals

Biotech Co. Has Promising AI-Accelerated Pipeline

Research Report
  ()
Rakovina Therapeutics Inc. (RKV:TSX.V) recently gained analyst coverage from First Berlin Equity Research. Read on to see why this company rates the stock a Buy.
Tags: Biotechnology / Pharmaceuticals